Introduction

Antibiotic therapy is a cornerstone of modern medicine. However, a subset of antibiotics carries significant musculoskeletal risk that clinicians, prescribers, and medico-legal practitioners must understand. Fluoroquinolone antibiotics, particularly levofloxacin, are associated with tendinopathy and tendon rupture. These adverse events have generated substantial litigation and regulatory scrutiny.

The Fluoroquinolone Drug Class

Fluoroquinolones are broad-spectrum antibiotics used widely for respiratory, urinary, and gastrointestinal infections. Commonly prescribed agents include ciprofloxacin, moxifloxacin, and levofloxacin. They work by inhibiting bacterial DNA gyrase and topoisomerase IV. Their efficacy is well established. Their safety profile, however, includes a recognised and serious risk of connective tissue damage.

Mechanism of Tendon Toxicity

Fluoroquinolones exert a direct toxic effect on tenocytes, the cells responsible for tendon maintenance and repair. Research demonstrates that these drugs inhibit tenocyte proliferation, stimulate matrix metalloproteinases, and reduce collagen synthesis. The net result is degradation of tendon matrix integrity. Magnesium chelation by fluoroquinolones may also impair cell signalling pathways critical to tendon homeostasis. The Achilles tendon is the most commonly affected structure, likely due to its high mechanical load and relatively poor vascular supply.

Levofloxacin and Achilles Tendon Injury

Levofloxacin is the L-isomer of ofloxacin and carries a particularly pronounced tendon risk profile within the class. Studies have reported that fluoroquinolone use increases the relative risk of Achilles tendon rupture by a factor of three to six compared to non-exposed populations. Case series document ruptures occurring during treatment and up to several months following cessation. This delayed presentation is clinically and legally significant. It means that causation is not always immediately apparent at the time of injury.

Risk Amplification Factors

Certain patient populations face substantially elevated risk. These include patients over the age of 60, those receiving concurrent corticosteroid therapy, patients with pre-existing renal impairment, and individuals with prior tendon pathology. Transplant recipients on immunosuppression represent another high-risk group. The co-prescription of corticosteroids with fluoroquinolones carries a synergistic risk. This combination has been consistently identified in medico-legal cases involving tendon rupture.

Regulatory Position

The Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) have issued formal guidance restricting fluoroquinolone use. Guidance published in 2019 advised that fluoroquinolones should not be used for mild or self-limiting infections, and should be avoided in patients with a history of tendon disorders related to this drug class. Prescribers are expected to counsel patients about musculoskeletal symptoms and to advise prompt cessation if tendon pain develops. Failure to adhere to these recommendations carries medico-legal consequence.

Medico-Legal Implications

Claims arising from fluoroquinolone-associated tendon injury typically proceed on grounds of negligent prescribing or failure to warn. Courts will scrutinise whether the prescriber identified contraindications, whether the prescription was justified given the indication, and whether the patient received adequate informed consent about tendon risk. The established regulatory framework and published guidance are central to establishing the standard of care. Expert evidence will generally address the causal link between drug exposure and injury, the foreseeability of harm, and the adequacy of prescribing decisions.

Conclusion

Fluoroquinolone antibiotics, and levofloxacin in particular, carry a well-documented risk of serious tendon injury including Achilles tendon rupture. This risk is not rare, is recognised in prescribing guidance, and disproportionately affects identifiable patient groups. Medico-legal practitioners should be alert to delayed onset presentations, the significance of concurrent corticosteroid use, and the evolving regulatory framework governing this drug class. A thorough review of prescribing records and clinical decision-making is essential in any case involving fluoroquinolone-associated tendon pathology.